Study of Adult Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) (PROSE)
What is the purpose of this trial?
A long-term observational registry in patients with atopic dermatitis initiating treatment with DUPIXENT® (dupilumab)
- Ages18 years and older
- Trial withRegeneron Pharmaceuticals, Inc.
- Start Date07/15/2019
- End Date12/01/2023
- Last Updated07/23/2019
- Study HIC#2000023360